ATAI
phase is a randomized double blind single dose study in moderate to severe patients | ATAI
Company
Deck Type
Sector
Industry
Deck date
January 2024
Slide
9 of 34
Related slides by other companies
Genprex
Investor Presentation
November 2024
phase dose in relapsed patients | Genprex
GH Research
Investor Presentation
May 2023
design of phase trial in | GH Research
Nuvectis Pharma
Investor Presentation
January 2024
phase underway fast track designation | Nuvectis Pharma
GH Research
Investor Presentation
November 2023
phase single dose efficacy | GH Research
Other recent decks by ATAI
See all presentations (13 decks)
Investor Presentation
October 2023
Investor Conference
May 2023
Investor Presentation
April 2023
Investor Presentation
March 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights